Optimizing Care for Patients with Advanced Hepatocellular Carcinoma: Current Standards and Future Directions with Immunotherapy

Published: Nov. 30, 2022, 5 a.m.

Host: Richard S. Finn, MD
\n\n Guest: Peter R. Galle, MD
\n\n\n \n

Combination immunotherapy (IO) is revolutionizing the management of advanced hepatocellular carcinoma (HCC). Listen in as Dr. Richard Finn and Dr. Peter Galle break down the most recent data around emerging strategies for using IO to treat your patients with HCC. What impact will these advances have on your clinical practice?